The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Aziz Zaanan
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS GmbH & Co. KG; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Jazz Pharmaceuticals; Merck Serono; MSD; Pierre Fabre; Sanofi; SERVIER
Research Funding - Amgen
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Jazz Pharmaceuticals; Merck; MSD; Pierre Fabre; SERVIER
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Christelle de la Fouchardière
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daichi-Sankyo; Gilead Sciences; Incyte; Jazz Pharmaceuticals; MSD Oncology; Pierre Fabre; SERVIER; Takeda
Research Funding - Agenus (Inst); MSD (Inst); Pierre Fabre (Inst); Servier (Inst); Summit Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre; SERVIER
 
Clélia Coutzac
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Jazz Pharmaceuticals; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Gilead Sciences; MSD Oncology; SERVIER
Speakers' Bureau - Amgen; Merck Serono; SERVIER
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Mundipharma; Pierre Fabre; Sandoz; SERVIER
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Biond Biologics; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Cardiff Oncology; Corcept Therapeutics; CytomX Therapeutics; Daiichi Sankyo; ElmediX; Fortvita; Fosum; Galapagos NV; Gilead Sciences; GlaxoSmithKline; Glenmark; Incyte; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Merus; Nordic Group; Novartis; Novocure; Oncoshot; Oxford BioTherapeutics; Pfizer; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda; Trishula Therapeutics; Zuellig Pharma; Zymeworks
 
Jeroen Dekervel
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb Belgium; Eisai; Incyte; Ipsen; Medtalks; MSD; Novartis; Roche; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Eisai; Ipsen; Merck; MSD; Roche; SERVIER
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Ipsen; Roche; SERVIER
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Fabio Franke
No Relationships to Disclose
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna; OncoDaily; Veda Life Sciences
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; BeOne; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; Gilead Sciences; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; i3 Health; i3 Health; IDEOlogy Health; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Regeneron; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Debbies Dream Foundation; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; OncoDaily; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Signatera; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Carina Biotech; Cartography Biosciences; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Johnson & Johnson/Janssen; Larkspur Biosciences Inc; Lilly; Marengo Therapeutics; Menarini; Merus; MSD; Novartis; One-carbon Therapeutics AB; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Syntelios AG; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Theriva Biologics; Tolremo
 
Chloe Spalding
Employment - Daiichi Sankyo Europe GmbH
Stock and Other Ownership Interests - Daiichi Sankyo
Consulting or Advisory Role - Bristol Myers Squibb (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH
 
Meredith Venerus
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - IQVIA
Consulting or Advisory Role - IQVIA
 
Fabricio Souza
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo; Merck
 
Alessandro Ghiretti
Employment - AstraZeneca; AstraZeneca (I); Chiesi Farmaceutici (I); Daiichi Sankyo
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I)
 
Mahmut Gumus
Honoraria - Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)
Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Gilead Sciences (Inst); MSD Oncology (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Incyte; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Revolution Medicines; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); BeOne (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Johnson & Johnson/Janssen; Merck Serono; Pierre Fabre; Takeda Science Foundation